Amgen delivered mixed Q4 results with a slight revenue decline but achieved a 6% increase in non-GAAP EPS due to share reductions. Management's optimistic outlook for 2020, emphasizing product launches and global expansion, provides some positive sentiment. However, concerns about net price declines and competitive pressures may temper immediate investor enthusiasm.

[0]